Effects of piroxicam on natriuresis and kaliuresis in hypertensives and healthy volunteers.
The effects of short-term piroxicam (P) treatment on natriuresis and kaliuresis were evaluated in 22 diuretic-treated hypertensives and 8 healthy subjects. Each hypertensive patient participated in three experimental periods, i.e., P 20 mg q.d. for 3 days and two control phases. Each healthy volunteer completed the six treatment phases, i.e., P 20 mg q.d. for 3 days, furosemide 40 mg orally in a single dose, P 20 q.d. for 3 days with furosemide 40 mg on the third day and three control phases. In healthy volunteers, P induced no change in 24-hour natriuresis and kaliuresis, but it reduced furosemide-stimulated natriuresis. In hypertensives with creatinine clearance (CCr) greater than 60 ml/min, P had no anti-natriuretic and anti-kaliuretic effects. In contrast, P induced a significant reduction in 24-hour natriuresis and kaliuresis in those with CCr less than 60 ml/min. Physicians should be aware of the potential risk of P-induced sodium retention and hyperkalemia, especially in patients with renal insufficiency, even though P was administered for only 3 days.
Lin
M S
MS
Department of Medicine, Cathay General Hospital, Taipei, Taiwan.
D000328:Adult; D000368:Aged; D005260:Female; D005665:Furosemide / Q000494:pharmacology; D006801:Humans; D006973:Hypertension / Q000652:urine*; D008297:Male; D008875:Middle Aged; D009318:Natriuresis / Q000187:drug effects; D010894:Piroxicam / Q000494:pharmacology*; D011188:Potassium / Q000652:urine*; D012964:Sodium / Q000652:urine*; D013997:Time Factors
D010894:Piroxicam; D005665:Furosemide; D012964:Sodium; D011188:Potassium